Sphere Fluidics announces Cyto-Mine® Chroma to accelerate and streamline workflows across expanded applications in biotherapeutic discovery and development

• Next generation of industry-leading Cyto-Mine platform will offer new capabilities to optimize single-cell analysis workflow efficiency
• Opens up new, multiplexed assays and applications for antibody discovery and cell line development, and allows entry into new markets such as cell and gene therapy.

1 October 2024 -- Cambridge, UK -- Sphere Fluidics, a leading provider of innovative droplet-based microfluidics solutions for single-cell analysis and isolation, today shared details of Cyto-Mine® Chroma, the second generation of its flagship Cyto-Mine platform. This new platform will offer enhanced capabilities, including multiplexing and greater assay flexibility, to further maximize the efficiency and precision of single-cell functional analysis workflows.

Cyto-Mine Chroma builds on the original Cyto-Mine platform’s ability to leverage picodroplet technology to encapsulate single cells, assess cellular function, and isolate target cells for downstream expansion or analysis. The new Chroma system will maintain Cyto-Mine’s best-in-class throughput enabling functional screening of millions of cells per hour and expand its multiplexing capabilities. With the upgrade to a four-color laser and detector system, Cyto-Mine Chroma significantly expands the utility of the original, single-laser Cyto-Mine platform by increasing the number of targets that can be analyzed for each encapsulated cell.

Launching in conjunction with the Company’s first multiplexed assay kit, the platform will enable researchers to conduct multiplexing in a single droplet, improving the throughput and precision of clone selection, by analyzing single cells for viability, productivity, and target specificity in one step. By accelerating the early selection of superior candidate cells, overall project timelines are reduced from months to weeks, while reducing effort and cost. “By combining multiplexing with our best-in-class cell throughput for functional screening of viable cells, the Cyto-Mine® Chroma platform will be a powerful new tool for our customers and will help them shave months off their project timelines.” Richard Hammond.

Cyto-Mine® Chroma, which will launch in Q1, 2025, is designed to support evolving needs in single cell analysis, facilitating cutting-edge, cost-effective research across broad applications, including antibody discovery, cell line development, and emerging areas such as cell therapy. Sphere Fluidics’ product roadmap includes a wide range of new assays and applications that can be developed on the platform, and the capacity for extended capabilities to be added via upgrade modules.

About Sphere Fluidics
Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems to enable researchers to find, analyze and isolate the most valuable cells, with ease and speed. Sphere Fluidics’ proprietary picodroplet microfluidic platforms are designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a picodroplet, while maintaining viability. Harnessing this technology, the Company’s range of novel microfluidic tools facilitate leading-edge research and accelerate biotherapeutic discovery and development, cell therapy, and synthetic biology workflows, streamlining the journey of discovery in labs, globally. Sphere Fluidics is based at Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of distributors. Visit: https://spherefluidics.com.